Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including...Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.展开更多
目的探讨个性化针对性护理干预在老年慢性阻塞性肺疾病稳定期患者中的应用效果及对微小RNA-146a、微小RNA-146b的影响。方法选取2021年1月—2022年12月收治的80例老年慢性阻塞性肺疾病稳定期患者作为研究对象,按照组间基线资料可比的原...目的探讨个性化针对性护理干预在老年慢性阻塞性肺疾病稳定期患者中的应用效果及对微小RNA-146a、微小RNA-146b的影响。方法选取2021年1月—2022年12月收治的80例老年慢性阻塞性肺疾病稳定期患者作为研究对象,按照组间基线资料可比的原则将其分对照组和观察组,各40例。对照组接受常规护理,观察组在对照组基础上接受综合护理干预,比较两组患者负性情绪、肺功能指标、微小RNA-146a、微小RNA-146b、睡眠质量等。结果护理干预前,两组患者SAS、SDS评分比较差异无统计学意义(P>0.05);护理干预后,观察组SAS、SDS评分低于对照组,差异有统计学意义(P<0.05)。护理干预后,观察组用力肺活量(forced vital capacity,FVC)、第1秒用力呼气量(forced ecpiratory volume in the first second,FEV1)、FEV1/FVC高于对照组,差异有统计学意义(P<0.05);观察组患者情感负担、经济负担、照顾负担评分低于对照组,差异有统计学意义(P<0.05);观察组患者匹兹堡睡眠质量量表(Pittsburgh sleep quality scale,PSQI)低于对照组,差异有统计学意义(P<0.05);护理干预后,观察组患者miR-146a及miR-146b水平高于对照组,差异有统计学意义(P<0.05)。结论慢性阻塞性肺疾病稳定期患者接受综合护理干预,能让其保持积极心态接受诊治,降低其自我感受负担,改善肺功能,保持良好的睡眠质量。展开更多
基金National Science and Technology Major Projects of Sudden Severe Acute Respiratory Infectious Diseases Treatment New Technology research and the New Scheme(No.2017 zx10204401)。
文摘Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.
文摘目的探讨个性化针对性护理干预在老年慢性阻塞性肺疾病稳定期患者中的应用效果及对微小RNA-146a、微小RNA-146b的影响。方法选取2021年1月—2022年12月收治的80例老年慢性阻塞性肺疾病稳定期患者作为研究对象,按照组间基线资料可比的原则将其分对照组和观察组,各40例。对照组接受常规护理,观察组在对照组基础上接受综合护理干预,比较两组患者负性情绪、肺功能指标、微小RNA-146a、微小RNA-146b、睡眠质量等。结果护理干预前,两组患者SAS、SDS评分比较差异无统计学意义(P>0.05);护理干预后,观察组SAS、SDS评分低于对照组,差异有统计学意义(P<0.05)。护理干预后,观察组用力肺活量(forced vital capacity,FVC)、第1秒用力呼气量(forced ecpiratory volume in the first second,FEV1)、FEV1/FVC高于对照组,差异有统计学意义(P<0.05);观察组患者情感负担、经济负担、照顾负担评分低于对照组,差异有统计学意义(P<0.05);观察组患者匹兹堡睡眠质量量表(Pittsburgh sleep quality scale,PSQI)低于对照组,差异有统计学意义(P<0.05);护理干预后,观察组患者miR-146a及miR-146b水平高于对照组,差异有统计学意义(P<0.05)。结论慢性阻塞性肺疾病稳定期患者接受综合护理干预,能让其保持积极心态接受诊治,降低其自我感受负担,改善肺功能,保持良好的睡眠质量。
